Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate
about
Optimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaAurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.The discovery of aurora kinase inhibitor by multi-docking-based virtual screening.The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsEstrogen Receptor Ligands: A Review (2013-2015).Detection of Ligand-induced Conformational Changes in the Activation Loop of Aurora-A Kinase by PELDOR SpectroscopyInhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy.Practical approaches to resolving reactive metabolite liabilities in early discovery.Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.The Aurora kinase inhibitors in cancer research and therapy.7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent1,3-Diallyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.3-Allyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-oneHigh-dimensional QSAR modelling using penalized linear regression model with L1/2-norm.Benzimidazole-Based Quinazolines: In Vitro Evaluation, Quantitative Structure-Activity Relationship, and Molecular Modeling as Aurora Kinase Inhibitors.4-(4-Nitro-benz-yl)morpholine.3-Benzyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.6-Bromo-1,3-bis-[(1,3-dioxolan-2-yl)meth-yl]-1H-imidazo[4,5-b]pyridin-2(3H)-oneCombined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.6-Chloro-3-nitro-N-(propan-2-yl)pyridin-2-amine.Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase-TPX2 protein-protein interaction.Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
P2860
Q27674324-72F16716-630F-40BC-B107-02D02DA47340Q27680538-6E5DC1A5-A818-4E37-BF01-2A2CFDF25324Q27703668-5995A55E-46A6-4F2E-ADB3-8136C1BE3A4EQ31814812-7F810309-6615-4FB6-ADD5-0E33EDE6C1DBQ34685403-EF8E9D17-EB4E-4B82-9C52-28A358F310F2Q34981765-AFC78F47-22AC-4EE0-B772-006DCF9A1B82Q36469916-7A325AB9-74C8-4BCA-8CE6-53A171153884Q37339491-9BB6BE09-6372-4AC5-B3D5-E5D8C5660992Q37515396-202BFF90-E86A-4455-BF99-1954FF7B9D05Q37685338-011FF63A-84D5-44F4-94C2-7460F5B26CCBQ38269781-C54446A2-3A0C-4105-AE7F-E4080CD4EEE5Q38695950-245B399C-DAB5-4E5E-9415-6FE4C0DAD165Q38756932-5C6280CF-B5CA-41DF-9EBE-4458BAC7262EQ38841925-40371799-618F-4F44-B29B-850BA3028C62Q39029955-58D6385E-3402-4ACC-A0EE-E988546AF15CQ39030181-DFB63A2F-9D04-416E-9217-56CE70351E2FQ39389810-B329CD83-0DB5-4648-8441-BC2177D677C9Q40101893-E11CC876-F54F-403B-9F02-FCDEC226AB54Q41780110-40280D64-35D5-48A0-BF8E-C484EE411775Q41822529-86DA1D76-0DC9-4144-9F33-AD8E33B508B9Q41901645-20DE3C84-BBAC-4B4B-B95B-0A8AD49195C6Q41984158-6848A0BD-E6F8-41D0-9974-BD8ABC529D04Q42768076-E84ABB84-68DB-41D6-A7E6-83D1782FB4ECQ47979119-5D225CB1-F028-4F79-99F0-B8C988D8DC9CQ54109642-C5ED19F9-D366-4E47-9D28-15E8D861FD29
P2860
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@ast
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en-gb
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@nl
type
label
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@ast
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en-gb
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@nl
prefLabel
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@ast
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en-gb
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@nl
P2093
P50
P3181
P356
P1476
Imidazo[4,5-b]pyridine derivat ...... clinical development candidate
@en
P2093
Alexis de Haven Brandon
Butrus Atrash
Chongbo Sun
Edward McDonald
Frederique Urban
Jonathan M Large
Julian Blagg
Jóhannes Reynisson
Magda Kosmopoulou
P304
P3181
P356
10.1021/JM100262J
P407
P577
2010-07-22T00:00:00Z